​Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I".

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".

"COVID-19 reminds us how acutely the virus can impact humanity. In fact, viruses existed long before the emergence of homo sapiens. In this book on the history of antiviral drug discovery, the human aspects are highlighted. In Chapter 1, the author regales us with several episodes where history was shaped by viruses causing smallpox, yellow fever, etc. The fascinating history of the first discovery of virus, tobacco mosaic virus, was also recounted. Chapters 2-5 covered four classes of viruses such as HIV, hepatitis viruses, influenza viruses and coronaviruses. Each chapter begins how the virus was discovered, followed by vaccine development, and then focuses on the discovery of small molecule antiviral drugs. For chemistry aficionados, the end of the book is replete with abundant of bibliography for further understanding of the minutia of the stories, followed by molecular structures of the antiviral drugs. This book is of interest to anyone who wants to know the science behind virus, vaccines and antiviral drugs. It is especially useful for healthcare professionals who are interested in knowing how viruses, vaccines and antiviral drugs are discovered"--

Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic. New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses. Covers the entire field of antiviral drug discovery and development Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2 Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the pharmaceutical industry and public health agencies.

Privileged Scaffolds in Drug Discovery is the most complete and up-to-date work in the area. Covering a wide range of privileged structures, it is a perfect reference for scientists involved in targeted drug development. The editors recruited epserts from several prestigious Chinese institutions to cover the areas of antiviral drugs, chalcone, pyrimidine, (benz)imidazoles, natural product-derived privileged scaffolds, N-Sulfonyl carboxamides, kinase inhibitors, antitumor molecules, antineurodegenerative drugs, triazoles, oxazolidinone, indole and indoline scaffolds, tigliane diterpenoids, peptide and peptide-based drugs, quassinoids, and others including pseudonatural products, macrocycles, stable peptides and peptidomimetics. The book also explores scaffolds in drug molecules approved in recent years. Privileged Scaffolds in Drug Discovery is a complete reference for researchers in drug discovery and organic synthesis, in academic and corporate settings, who are investigating privileged structures upon which to base new drugs. Researchers in medicinal chemistry and chemical biology will also find the contents of this book valuable. - Provides wide coverage of privileged scaffolds in new drug discovery - Includes complex and diverse natural product scaffolds - Covers applications to peptides and peptide-based drugs

Advances in Prodrugs: Design and Therapeutic Applications provides a versatile tool in prodrug design and development as well as a concrete perspective on clinical and preclinical studies currently available on prodrugs. The first part of this book discusses different chemical classes of prodrugs, with particular emphasis on metabolic pathways and mechanisms involved in the activation of their functional groups. The second part of the book covers therapeutic applications of prodrugs against the most discussed diseases, providing detailed discussion on recent achievements in the field. This book offers researchers involved in drug discovery key criteria for the successful development of prodrug-based therapeutic tools.Prodrugs are inactive drug precursors which undergo different chemical transformation by metabolic processes to provide pharmacologically active compounds. Prodrugs include a broad range of structurally diverse molecules employed for the treatment of several diseases. - Highlights chemistry and pharmacology-related aspects, offering a versatile tool for readers involved in prodrug development and study - Discusses in-depth treatment of several activation mechanisms and applications for disease treatments - Covers a range of topics from basic contents, design, and mechanisms of actions to current applications in drugs

While research teams are producing relevant and valid knowledge for health promotion, there is not yet a structured manual and distinct field of health promotion research. This timely "state-of-the-art" handbook contributes to the structuring of such a field of research. This collection of original contributions explores the major epistemological, methodological, and ethical challenges facing health promotion research. It brings together experts from different "research traditions" that coexist in the field. The handbook covers the existing knowledge production and sharing practices to delineate the "discipline" and its agenda for future research. Ultimately, it contributes to the creation of a global community of health promotion researchers. The handbook is organized by four types of practices (what people actually do) studied in health promotion; the practices of: Individuals and populations in relation to their health and its determinants Professionals who intervene to improve population health Policy-makers and institutions involved in the advocacy, design, and implementation of policies and programs Researchers and innovators (academic scholars and global agencies) through which investment in research and production of evidence-based guidelines are made. Global Handbook of Health Promotion Research, Vol. 1: Mapping Health Promotion Research is a highly relevant reference tool for researchers and graduate students in health promotion, public health, education and socio-health sciences; practitioners in health, medical, and social sectors; policy-makers; and health research administrators.